Kezar life sciences, inc. (KZR)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17
Operating expenses:
Research and development

7,457

7,431

7,080

6,925

5,927

4,672

4,664

5,228

3,572

1,557

1,445

General and administrative

3,021

2,566

2,601

2,430

2,382

1,754

1,600

1,722

1,514

635

436

Total operating expenses

10,478

9,997

9,681

9,355

8,309

6,426

6,264

6,950

5,086

2,192

1,881

Loss from operations

-10,478

-9,997

-9,681

-9,355

-8,309

-6,426

-6,264

-6,950

-5,086

-2,192

-1,881

Interest income

466

418

533

637

667

644

601

175

139

112

1

Net loss

-10,012

-9,579

-9,148

-8,718

-7,642

-5,782

-5,663

-6,775

-4,947

-2,080

-1,880

Net loss per common share, basic and diluted

-0.30

-0.50

-0.48

-0.46

-0.40

7.88

-0.30

-3.31

-6.53

-3.31

-3.30

Weighted-average shares used to compute net loss per common share, basic and diluted

32,867

19,123

19,095

19,073

19,042

19,301

18,955

2,044

757

628

569